Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase 1 1

Status

Unknown 3Completed 3

Sponsor Class

INDUSTRY 10OTHER 8NIH 6NETWORK 4

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Leukemia, Myeloid, Acute 15Leukemia 15Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 10Leukemia, Erythroblastic, Acute 10Leukemia, Megakaryoblastic, Acute 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma 7Congenital Abnormalities 7Prostatic Neoplasms 6Breast Neoplasms 6Myelodysplastic Syndromes 4Anemia, Refractory, with Excess of Blasts 4Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Leukemia, Promyelocytic, Acute 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Burkitt Lymphoma 2Sarcoma, Myeloid 1Ovarian Neoplasms 1Neutropenia 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Mitoxantrone × Clear all
NCT00331344 2017-10-31

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy

National Cancer Institute (NCI)

Phase 1/2 Completed
100 enrolled 10 charts
Genitourinary

Prostatic Neoplasms

NCT00058084 2017-02-23

Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
80 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003633 2013-12-19

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 1 Unknown
12 enrolled
Genitourinary

Prostatic Neoplasms

NCT00003183 2013-12-04

Mitoxantrone and G-CSF in Treating Patients With Metastatic Prostate Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
64 enrolled
Genitourinary

Prostatic Neoplasms

NCT00627354 2011-05-16

Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Completed
90 enrolled
Genitourinary

Prostatic Neoplasms

NCT00006114 2011-03-01

Combination Chemotherapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

National Cancer Institute (NCI)

Phase 2 Unknown
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡